Acute kidney injury (AKI) represents a complex clinical condition associated with significant morbidity and mortality. Approximately, 19-33% AKI episodes in hospitalized patients are related to drug-induced nephrotoxicity. Although, considered safe, non-steroidal anti-inflammatory drugs such as diclofenac have received special attention in the past years due to the potential risk of renal damage. Vinpocetine is a nootropic drug known to have anti-inflammatory properties. In this study, we investigated the effect and mechanisms of vinpocetine in a model of diclofenac-induced AKI. We observed that diclofenac increased proteinuria and blood urea, creatinine, and oxidative stress levels 24 h after its administration. In renal tissue, diclofenac also increased oxidative stress and induced morphological changes consistent with renal damage. Moreover, diclofenac induced kidney cells apoptosis, up-regulated proinflammatory cytokines, and induced the activation of NF-B in renal tissue. On the other hand, vinpocetine reduced diclofenacinduced blood urea and creatinine. In the kidneys, vinpocetine inhibited diclofenac-induced oxidative stress, morphological changes, apoptosis, cytokine production, and NF-B activation. To our knowledge, this is the first study demonstrating that diclofenac-induced AKI increases NF-B activation, and that vinpocetine reduces the nephrotoxic effects of diclofenac. Therefore, vinpocetine is a promising molecule for the treatment of diclofenac-induced AKI.
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) represent the most popular class of drugs currently prescribed and used worldwide, reaching over than 70 million prescriptions each year in the USA. This high number of prescription correlates with many cases of NSAIDs intoxication in humans registered by The Association of the Poison Control Centers' National Poison Data System (AAPCC NPDS) in the last years [1, 2] . NSAIDs acute and chronic intoxications are linked to increasing morbidity and mortality and have a direct impact on public health costs [1, 2] . NSAIDs are extremely efficient as analgesic, anti-inflammatory, and antipyretic agents, and are used routinely to treat varied forms of acute pain and inflammation [2, 3] . However, the indiscriminate use of NSAIDs represents a challenge to the public health due to their countless adverse effects. Major adverse effects of NSAIDs include gastrointestinal damage and acute kidney injury (AKI), and in more severe cases, increased risk of serious cardiovascular dysfunctions [2, 4] . The main mechanisms of action of NSAIDs involve the inhibition of cyclooxygenase enzymes isoforms 1 (COX-1) and 2 (COX-2), thereby preventing the synthesis of their downstream effector prostaglandins and thromboxane A 2 [2] . The two main types of acute renal failure induced by NSAIDs are hemodynamically-mediated nephritis and acute interstitial nephritis, both associated with the low levels of prostaglandins due to the COX inhibition by NSAIDs [2, 5] .
Diclofenac (2-[(2,6-diclorophenyl)amino]phenyl acetate), a non-selective NSAID, is a phenyl acetic acid derivative that presents analgesic, antipyretic, and anti-inflammatory activities [6] . In chronic and acute pain conditions, diclofenac exhibits high efficacy and good tolerability [3] . Commercial diclofenac (Voltaren ® ) is the most common NSAID prescribed for myalgia, osteoarthritis, rheumatoid arthritis, and other rheumatic disorders [7] [8] [9] . Similarly to other NSAIDs, diclofenac adverse effects include gastrointestinal disorders, liver injury, hypersensitive reactions, hematotoxicity and AKI [6, 10, 11] . Prostaglandins maintain normal glomerular filtration rate (GFR) and the inhibition of their synthesis by diclofenac leads to abnormal renal function, the decline in glomerular hydraulic pressure, and ultimately AKI [2] . The direct effect of diclofenac-induced renal injury depends on targeting kidney's mitochondria leading to the production of reactive oxygen species (ROS) causing DNA lesions and apoptosis [8, 12] . This compilation of data raises the concern about the cytotoxic effects related to abuse and/or overdose of NSAIDs such as diclofenac. Vinpocetine (ethyl apovincamine-22-oate) is a synthetic compound belonging to the class of nootropic drugs. Vinpocetine is a derivative of vincamine molecule, an alkaloid extracted from the leaves of Vinca minor [13, 14] . The clinical use of vinpocetine includes the management of cerebrovascular disorders such as stroke and cerebral hemorrhage as well as cognitive dysfunctions [15, 16] . Growing body of evidence also point out to the antiinflammatory effects of vinpocetine [13, 14, 17, 18] . Vinpocetine acts as an inhibitor of phosphodiesterase-1 (PDE-1) activity, regulating the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) [14] . Nevertheless, vinpocetine inhibits NF-B activation and its downstream proinflammatory mediators such as TNF-␣ and IL-1␤ [13, 14, 17, 18] independently of its PDE inhibition-related mechanisms [14, 19] . Vinpocetine also presents antioxidant effects that account for its anti-inflammatory actions [13, 17] .
The mechanisms of diclofenac-induced AKI need further investigation for a better understanding of its physiopathology and therapeutic profile. Glucocorticoids are one of the choices for AKI management [20, 21] . Considering that this class of drugs acts by inhibiting NF-B by varied mechanisms [22] , it is conceivable that NF-B inhibitors could present beneficial effects in diclofenacinduced AKI. Given that glucocorticoids treatment induces severe side effects, this study investigated the efficacy of vinpocetine in diclofenac-induced AKI.
Materials and methods

Animals
The experiments were performed on male one-month-old Swiss mice, weighing between 20 and 25 g from Londrina State University, Paraná State, Brazil. Mice were housed in standard clear plastic cages with free access to water and food, light/dark cycle of 12/12 h and controlled temperature. Mice were maintained in the vivarium of the Department of General Pathology, Londrina State University for at least two days before the experiments. Mice were used only once and were acclimatized to the testing room at least 1 h before the experiments, which was conducted during the light cycle. At the end of experiments described in the following items, mice were anesthetized with isoflurane 3% (Abbot, Abbott Park, IL, USA) by inhalation overdose, and terminally euthanized by cervical dislocation followed by decapitation. The Londrina State University Ethics Committee on Animal Research and Welfare approved animal care and handling procedures under the process number 27500.2014.40. All efforts were made to minimize the number of animals used and their suffering.
Drugs
Materials were obtained from the sources as follows: sodium diclofenac (Neutaren ® ) was purchased from Novartis Biociências 
Experimental design
In the first set of experiments, mice received toxic doses of diclofenac (200 and 300 mg/kg, 100 l, p.o.) administration and 24 h after, blood levels of urea, creatinine, superoxide anion, and lipid peroxidation were measured to determine the adequate nephrotoxic dose. Afterward, mice were treated with diclofenac (200 mg/kg, 100 l, p.o.) 30 min prior to the treatment with vinpocetine (0.3, 1, or 3 mg/kg, 100 l, p.o.) or vehicle (sterile saline, 100 l, p.o.). Twenty-four hours after diclofenac administration, urea and creatinine blood levels were evaluated to determine the best dose of vinpocetine. The dose of 3 mg/kg of vinpocetine was selected for the following experiments: blood ALT and AST levels; proteinuria; histopathological features; cytokine production (ELISA); NF-B (immunohistochemistry and ELISA); COX-2 and cMyc immunohistochemistry. Diclofenac and vinpocetine doses, as well as the time of samples collection, were based on previous studies [8, 13, 17] . All analyses in renal tissue collected described above were performed using the entire organ.
Renal function tests
Blood samples were collected by cardiac puncture 24 h after the diclofenac administration and added into microtubes containing anticoagulant (EDTA, 5000 IU/ml, Sigma Chemical Co., St. Louis, MO, USA). The plasma was separated by centrifugation (200 × g, 10 min, and 4 • C). Plasma samples were processed according to the manufacturer's instructions (Labtest Diagnóstico S.A., Lagoa Santa, MG, Brazil) to evaluate urea and creatinine levels as indicators of nephrotoxicity. Results are presented as milligram per deciliter of plasma urea or creatinine. Urine was collected 24 h after the diclofenac administration by the application of gentle pressure over the bladder and added into microtubes for proteinuria analysis using Lowry's method.
Enzymatic markers of liver injury
Blood samples were collected by cardiac puncture 24 h after diclofenac administration or 10 h after acetaminophen administration (650 mg/kg, i.p.), and added into microtubes containing anticoagulant (EDTA, 5000 IU/ml, Sigma Chemical Co., St. Louis, MO, USA). The plasma was separated by centrifugation (200 × g, 10 min, and 4 • C). Plasma samples were processed according to the manufacturer's instructions (Labtest Diagnóstico S.A., Lagoa Santa, MG, Brazil) to evaluate ALT and AST levels as indicators of hepatotoxicity. Results are presented as U/l of plasma ALT or AST.
2.6. Ferric-reducing ability potential and free radical scavenging ability assays
The kidney was collected 24 h after the diclofenac administration, immediately homogenized with 500 l of 1.15% KCl and centrifuged (10 min, 200 × g, and 4 • C). The ability of the samples to resist oxidative damage was determined as ferric-reducing ability potential (FRAP) and free-radical scavenging ability (ABTS) assays [23] . For the FRAP assay, 15 l of supernatant was mixed with 45 l of deionized water and 200 l of freshly prepared FRAP reagent (Sigma Chemical Co., St. Louis, MO, USA). The reaction mixture was incubated at 37 • C for 30 min, and the absorbance was measured at 595 nm. For the ABTS assay, the ABTS solution (Sigma Chemical Co., St. Louis, MO, USA) was diluted with phosphate buffer saline at pH 7.4 to an absorbance of 0.80 at 730 nm. Then, 200 l of diluted ABTS solution was mixed with 15 l of the supernatant. After 6 min, the absorbance was measured at 730 nm. The results were equated against a Trolox standard curve (1.5-30 mol/l, final concentrations) (Sigma Chemical Co., St. Louis, MO, USA). The protein levels in the samples were used for data normalization, and the results are expressed as nmol of Trolox (Sigma Chemical Co., St. Louis, MO, USA) equivalent per milligrams of protein in both assays.
Reduced glutathione (GSH) assay
The levels of GSH in renal tissue samples were determined using a spectrophotometric method. Kidneys were collected 24 h after the diclofenac administration and processed following a previously described protocol [24] . The results were presented as mmols of GSH per milligrams of protein (Sigma Chemical Co., St. Louis, MO, USA).
Nitroblue tetrazolium reduction assay
For nitroblue tetrazolium (NBT) (Amresco, Solon, OH, USA) reduction assay, blood and kidney tissue were collected 24 h after the diclofenac administration as described previously [25] . Briefly, the kidney was homogenized with 500 l of 1.15% KCl, and aliquots of 50 l of homogenate were transferred to a 96-well plate, followed by the addition of 100 l of NBT solution, and maintained at 37 • C in a warm bath for 5 min. For blood analysis, samples were collected by cardiac puncture 24 h after the diclofenac administration, and added into microtubes containing anticoagulant (EDTA, 5000 IU/ml, Sigma Chemical Co., St. Louis, MO, USA). The plasma was separated by centrifugation (200 × g, 10 min, and 4 • C). The supernatant was removed, and the formazan precipitated was then solubilized by adding 120 l of 2 M KOH (Sigma Chemical Co., St. Louis, MO, USA) and 140 l of dimethyl sulfoxide (DMSO, Sigma Chemical Co., St. Louis, MO, USA). The optical density was measured at 600 nm using a microplate spectrophotometer reader (Multiskan GO Microplate Spectrophotometer, Thermo Scientific, Vantaa, Finland). The protein levels in the samples were used for data normalization and the results were presented as NBT reduction (optical density [OD] per milligram of protein or dl of plasma).
Lipid peroxidation assay
The levels of thiobarbituric acid (TBA)-reactive substances (TBARS), primarily malondialdehyde (MDA), were quantified spectrophotometrically using an adapted method as previously described [26] . Tissue homogenate or plasma reacted with TBA to form MDA-(TBA)2 complexes, and the proteins were precipitated with trichloroacetic acid. Samples were incubated for 15 min in a boiling water bath and transferred to an ice bath. MDA, an intermediate product of lipid peroxidation, was determined by the difference between absorbance at 535 and 572 nm using a microplate spectrophotometer reader (Multiskan GO Microplate Spectrophotometer, Thermo Scientific, Vantaa, Finland). The results are presented as Lipid peroxidation ( OD A535-A572/mg of protein or dl of plasma).
Histopathological analysis
For renal histopathological analysis, kidneys were collected 24 h after diclofenac administration, fixed in 4% paraformaldehyde and dehydrated in a graded series of ethanol solutions for paraffin embedding. Five m sections of cortical and medullary zones were prepared and stained with hematoxylin & eosin (H&E) and periodic acid-Schiff (PAS). H&E and PAS stained sections were examined at 40x magnification and scored by a pathologist using light microscopy, and a semi-quantitative evaluation of renal tissue damage was estimated in 10 high power fields (HPF) as described previously with modifications [27] . The total histopathological score was assayed considering morphological alterations in the: 1) glomerulus; 2) cortical and medullar loss of brush border; 3) vacuolation; and 4) degeneration of epithelial tubular cells. The degree of renal damage was classified on a scale of 0-3 (0: normal, 1: mild, 2: moderate, 3: severe). Results are presented as the total histopathological score. The highest possible total score was 12.
Cytokine production
For cytokine production assessment, samples of renal tissue were collected 24 h after diclofenac administration. The samples were homogenized in 500 l of the appropriate buffer containing protease inhibitors. Cytokine levels were determined as described previously by an enzyme-linked immunosorbent assay (ELISA) using eBioscience kits (eBioscience, San Diego, CA, USA) accordingly with manufacturer instructions. The results were expressed as picograms (pg) of cytokine per 100 mg of tissue.
Immunohistochemistry
For immunohistochemical reaction, paraffin embedded kidney sections at 4 m were dewaxed, hydrated and heat-treated in 1 mM EDTA buffer for antigenic unmasking on microwave at 95.8 • C for 20 min. Sections were incubated overnight at room temperature with rabbit polyclonal anti-NF-B p65 (Bioss, Sacrament, CA, USA; catalog #bs-0456R, lot #999980W, 1:250), rabbit polyclonal anti-c-Myc (Santa Cruz Biotechnology, Santa Cruz, CA, USA; catalog #sc-40, 1:100. Prof. Isabelle Bourdeau from Université de Montréal, Québec, Canada, gently donated this reagent), or rabbit polyclonal anti-COX-2 (Bioss, Sacrament, CA, USA; catalog #bs-0732R, 1:200. Prof. Isabelle Bourdeau from Université de Montréal, Québec, Canada, gently donated this reagent) followed by conjugation to the secondary antibody mouse/Rabbit ImmunoDetector HRP/DAB (BioSB, Santa Barbara, CA, USA; catalog #BSB0005, lot #0005GFI18). Immunohistochemically staining was performed using the polymer-peroxidase based method, followed by development with diaminobenzidine (Sigma Chemical Co., St. Louis, MO, USA). A methodical negative control went through the first step of the procedure (incubation with the vehicle instead of the primary antibody). Histological slides were analyzed under the optic microscope to identify areas that best represented NF-B p65, c-Myc, or COX-2 immunostaining, whereas brownish color was considered to be evidence of a positive expression. From each sample, photomicrographs of 800 × 600 pixels were obtained from 4x and 40x magnification fields, using a Samsung camera (three images/slice), adapted in the optic microscope. Digitally acquired images were analyzed in the ImageJ 1.44 software for Windows (Java image software in public domain: http://rsb.info.nih.gov/ij/), using the threshold tool with color-based selection for positive staining. Routines for image analysis were defined in ImageJ macro language and performed on RGB images without further treatment. The number of pixels in the selected color range was divided by the total number of pixels in each field. Four slices per sample of kidney tissue were Fig. 1 . Diclofenac increases plasma levels of urea, creatinine, superoxide anion production, and lipid peroxidation. Mice received the stimulus with diclofenac (200 or 300 mg/kg, p.o.) and blood was collected after 24 h for the determination of plasma urea (A), creatinine (B), superoxide anion production (C), and lipid peroxidation levels (D). Results are expressed as mean ± SEM, n = 6 mice per group per experiment, two independent experiments ( * p < 0.05 vs. control group, one ANOVA followed by Tukey's post hoc).
analyzed and data were averaged. Results were expressed by the relation between the immunopositive area fraction per total area fraction as the percentage (%) of NF-B, c-Myc, or COX-2 staining. Control and experimental kidneys were processed under the same conditions.
NF-ÄB activation
The determination of NF-B activation in renal tissue was performed accordingly with manufacturer instructions. The kidney was collected 24 h after diclofenac administration and homogenized in ice-cold lysis buffer (Cell Signaling Technology, Beverly, MA, USA). The homogenates were centrifuged (16,100 g × 10 min × 4 • C) and the supernatants used to assess the levels of total and phosphorylated NF-B p65 subunit by ELISA using PathScan kits #7836 and #7834, respectively (Cell Signaling Technology, Beverly, MA, USA). The results are presented as the sample ratio (phospho-p65/total-p65) measured at 450 nm.
Statistical analysis
Results are presented as mean ± standard error means (SEM) of measurements made on six mice in each group per experiment, except for those in the histopathological score (12 mice in each group per experiment). Results are representative of two independent experiments. Data were analyzed using one-way ANOVA followed by Tukey's post hoc and for categorical variables, Kruskal-Wallis followed by Dunn's post hoc, using the statistical software GraphPad Prism 6.01 (GraphPad Software Inc., La Jolla, CA, USA). Statistical differences were considered significant when p < 0.05.
Results
Diclofenac induces kidney injury and increases blood oxidative stress
First, the diclofenac dose capable of inducing kidney injury was determined considering previously described doses [8] . Mice received the stimulus with diclofenac (200 or 300 mg/kg, p.o.) and a blood sample was collected after 24 h for the evaluation of urea, creatinine, superoxide anion production, and lipid peroxidation (Fig. 1) . Diclofenac at 200 and 300 mg/kg elevated plasma urea (Fig. 1A) , creatinine (Fig. 1B) , superoxide anion production (Fig. 1C) , and lipid peroxidation (Fig. 1D ) when compared to control group. Given there were no difference between the doses in these four parameters, the diclofenac at 200 mg/kg was chosen for the following experiments.
Vinpocetine reduces diclofenac-induced increase of plasma urea and creatinine and proteinuria
Next, the vinpocetine dose capable of reducing diclofenacinduced increase in urea and creatinine plasma levels, and proteinuria was evaluated (Fig. 2) . Mice received the stimulus with diclofenac (200 mg/kg, p.o.) and after 30 min were treated with vin- pocetine (0.3, 1, or 3 mg/kg, p.o.). Blood sample and urine were collected 24 h after diclofenac administration. Diclofenac increased urea and creatinine plasma levels, which were reduced by vinpocetine treatment in a dose-dependent manner ( Fig. 2A, B) . The doses of 1 and 3 mg/kg reduced urea plasma levels (IC 50 0.965 mg/kg) whereas only the dose of 3 mg/kg reduced creatinine plasma levels (IC 50 2.005 mg/kg) (Fig. 2B) . The dose of 3 mg/kg reduced 71% of creatinine levels. Therefore, vinpocetine at 3 mg/kg was chosen for the following experiments. Diclofenac also increased proteinuria, which was reduced in vinpocetine-treated mice (Fig. 2C) . Furthermore, diclofenac did not change kidney fresh weight (data not shown). Vinpocetine (3 mg/kg, p.o.) alone did not induce any changes in these markers ( Fig. 2A-C) .
Diclofenac does not induce liver injury
The next step was to evaluate whether diclofenac induces injury of organs other than the kidney. Mice received the stimulus with diclofenac (200 mg/kg, p.o.) and after 30 min were treated with vinpocetine (3 mg/kg, p.o.). Mice were also stimulated with diclofenac (200 mg/kg, p.o.) or acetaminophen (650 mg/kg, i.p.) without further treatment. Twenty-four or 10 h after diclofenac and acetaminophen stimulus, respectively, a blood sample was collected for the evaluation of ALT and AST levels. Diclofenac did not increase the levels of AST (Fig. 2D) and ALT (Fig. 2E) , whereas the known hepatotoxic drug acetaminophen increased both AST (Fig. 2D) and ALT (Fig. 2E ) levels. Vinpocetine (3 mg/kg, p.o.) alone did not induce any changes in these markers (Fig. 2D, E) .
Vinpocetine inhibits diclofenac-induced kidney oxidative stress
The effect of vinpocetine in diclofenac-induced oxidative stress was evaluated by the antioxidant defense status (FRAP, ABTS, and GSH assays), superoxide anion production, and lipid peroxidation (Fig. 3) . Mice received the stimulus with diclofenac (200 mg/kg, p.o.) and after 30 min were treated with vinpocetine (3 mg/kg, p.o.). The kidney was collected 24 h after diclofenac administration. Diclofenac reduced antioxidant defenses in renal tissue as observed by reductions in FRAP (Fig. 3A) and ABTS assays (Fig. 3B) , and GSH levels (Fig. 3C) . Additionally, superoxide anion production (Fig. 3D) , and lipid peroxidation (Fig. 3E) were increased in diclofenac-stimulated animals. Treatment with vinpocetine reverted diclofenac-induced depletion of antioxidant defenses (Fig. 3A-C) as well as inhibited superoxide anion production (Fig. 3D) , and lipid peroxidation (Fig. 3E) . Vinpocetine (3 mg/kg, p.o.) alone did not induce any changes in these markers.
Vinpocetine reduces diclofenac-induced kidney histopathological changes
Histopathological changes were evaluated using H&E (A-D, J-M) and PAS (E-I, N-Q) staining. Mice received the stimulus with diclofenac (200 mg/kg, p.o.) and after 30 min were treated with vinpocetine (3 mg/kg, p.o.). The kidney was collected 24 h after diclofenac administration. Fig. 4A , E shows kidney from control group mice presenting intact glomeruli, intact proximal and distal convoluted tubules in the cortical region. On the other hand, kidneys from animals that received diclofenac (Fig. 4C, G) presented 
.). The kidney was collected 24 h after the stimulus for the determination of FRAP (A), ABTS (B), GSH (C), superoxide anion production (D), and lipid peroxidation levels (E).
Results are expressed as mean ± SEM, n = 6 mice per group per experiment, two independent experiments ( * p < 0.05 vs. control group; # p < 0.05 vs. 0 mg/kg group, one ANOVA followed by Tukey's post hoc). irregular shape glomeruli and Bowman's capsule damage as noted by glomeruli deformation (Fig. 4G ) and glomeruli tip lesions (as observed by the merge between the Bowman's capsule and the epithelial tubular cells) (Fig. 4I) . Importantly, these changes were reverted by vinpocetine (Fig. 4H, I ). Moreover, diclofenac induced tubular dilatation accompanied by flattened epithelium (Fig. 4C , G) as well as loss of brush borders in the cortical proximal convoluted tubules (Fig. 4G) . Vinpocetine-treated mice showed mild tubular cell vacuolation, pronounced reduction in the glomeruli damage, tubular dilatation, and loss of the brush border (Fig. 4D, H , and I). Of note, diclofenac did not induce morphological changes in the macula densa. Diclofenac also induced morphological changes in the medullary portion of the kidney (such as loss of the brush border), which were reduced by vinpocetine treatment (Fig. 4J-Q) . Fig. 4J , N show normal kidney medullary portion. Fig. 4R shows the total histopathological score of experimental groups. Vinpocetine (3 mg/kg, p.o.) alone did not induce histopathological changes (Fig. 4B, F , K, O, and R).
Vinpocetine reduces diclofenac-induced kidney cytokine production
The effect of vinpocetine on diclofenac-induced kidney cytokine production was evaluated. Mice received the stimulus with diclofenac (200 mg/kg, p.o.) and after 30 min were treated with vinpocetine (3 mg/kg, p.o.). Kidney was collected 24 h after diclofenac administration. Diclofenac increased the production of IL-1␤ (Fig. 5A ), IL-6 (Fig. 5B), IFN-␥ (Fig. 5C ), IL-33 (Fig. 5D) , and TNF-␣ (Fig. 5E ) in the kidney when compared to control group. On the other hand, vinpocetine treatment was able to reduce diclofenac-induced proinflammatory cytokine production ( Fig. 5A-E) . Vinpocetine (3 mg/kg, p.o.) alone did not induce any changes in cytokine levels.
Vinpocetine inhibits diclofenac-induced kidney NF-ÄB activation
Next, the role of NF-B in diclofenac-induced AKI was investigated. NF-B activation was determined by immunohistochemistry (NF-B p65 protein expression) (Fig. 6 ) and ELISA (phosphorylatedp65/total-p65 ratio) (Fig. 7) assays. Mice received the stimulus with diclofenac (200 mg/kg, p.o.) and after 30 min were treated with vinpocetine (3 mg/kg, p.o.). The kidney was collected 24 h after diclofenac administration. Diclofenac increased kidney NF-B p65 immunohistochemical staining (Fig. 6C , G, and I) as well as increased ELISA phosphorylated p65/total-p65 ratio (Fig. 7 ) when compared to control group. Given the elevation in phosphorylated p65/total-p65 ratio, diclofenac not only increases NF-B expression as well as increases its activation in renal tissue. Vinpocetine treatment reduced diclofenac-induced NF-B p65 immunohistochemical staining (Fig. 6D, H, and I ) and phosphorylated p65/total-p65 ELISA ratio (Fig. 7) . Vinpocetine (3 mg/kg, p.o.) alone did not induce any changes in these markers (Figs. 6B, F, and I; and 7).
Vinpocetine inhibits diclofenac-induced kidney apoptosis
The effect of vinpocetine on diclofenac-induced apoptosis was then investigated by immunohistochemistry (c-Myc protein expression) (Fig. 8) . Mice received the stimulus with diclofenac (200 mg/kg, p.o.) and after 30 min were treated with vinpocetine (3 mg/kg, p.o.) . The kidney was collected 24 h after diclofenac administration. Diclofenac increased kidney c-Myc immunohistochemical staining (Fig. 8C, G, and I ) when compared to control group. Vinpocetine treatment reduced diclofenac-induced c-Myc immunohistochemical staining (Fig. 8D, H, and I ). Vinpocetine (3 mg/kg, p.o.) alone did not induce any change in this marker (Fig. 8B, F, and I) .
Diclofenac does not change kidney COX-2 expression
Last, the effect of diclofenac in kidney COX-2 expression was evaluated. Mice received the stimulus with diclofenac (200 mg/kg, p.o.) and after 30 min were treated with vinpocetine (3 mg/kg, p.o.). The kidney was collected 24 h after diclofenac administration. Neither diclofenac nor vinpocetine changed kidney COX-2 immunohistochemical staining (Fig. 9 ) when compared to control group.
Discussion
In this study, vinpocetine treatment reduced diclofenac-induced AKI as observed by inhibition of plasma urea and creatinine levels. In addition, vinpocetine reduced diclofenac-induced histopathological changes (in cortical and medulla portions) and kidney damage by a mechanism related to inhibition of cytokine production, oxidative stress, NF-B activation, and apoptosis. To our knowledge, these data show for the first time that diclofenacinduced AKI increases NF-B activation, and that vinpocetine reduces the nephrotoxic effects of diclofenac.
The nephrotoxic effect of diclofenac was previously demonstrated in diverse experimental models using both in vitro and in vivo analysis [8, 12, 28, 29] . The attention of the scientific community about diclofenac deleterious effects to renal system gained strength after the publication of reports describing the threatening effects of diclofenac to several species of wild vultures worldwide [30] [31] [32] [33] [34] . For instance, diclofenac residues in the blood of Indian vultures Gyps bengalensis correlates with the decline in their population [30, 33] . Other species of vultures Gyps endangered in Africa are equally susceptible to the noxious effects of diclofenac [32] . Accordingly, the decline in Gyps bengalensis vultures populations in Nepal and India reduced after the withdrawal of veterinary diclofenac from the market [31] . Regarding human intoxication, diclofenac also induces nephrotoxicity in newborns due to diclofenac ingestion by mothers [35] , adults without other risk factors than diclofenac administration [36, 37] , children [38] , and elderly patients [36, 39, 40] . In the first case, three newborns presented renal failure and one of them died [35] . In addition, ingestion of 2.5 g of diclofenac caused transient acute renal failure with recovery in 2 days [41] , and a patient that used diclofenac for chronic muscular pain and knee arthropathy presented acute tubular injury due to medication [37] . In an environmental con- text, diclofenac that is eliminated in urine reaches affluent rivers and causes kidney and liver injuries in fishes [42, 43] . Therefore, these set of data point out to diclofenac as a potential inductor of AKI and raise concern about the ecologic impact of the ingestion of diclofenac despite its clinical efficacy. It is also noteworthy to mention that diclofenac is related to a series of severe complications apart from AKI [44] [45] [46] .
Clinical AKI is often diagnosed by an increase in blood urea nitrogen and creatinine, which characterize a critical risk factor for mortality in hospitalized and/or in intensive care unit patients [47] . Additionally, increase in blood oxidative stress is commonly found in AKI [48, 49] . In the present experimental condition, diclofenac increased blood creatinine, urea, and oxidative stress levels 24 h after the stimulus, which corroborates the toxic effect of this molecule. Diclofenac induced deformation and formation of tip lesions in the glomeruli, which are indicative of renal damage [50] . In addition, diclofenac induced tubular dilatation and loss of brush border as observed by H&E and PAS staining data. Inhibition of prostaglandin synthesis leads to the loss in glomeruli basic function impairing GFR and renal metabolism [51, 52] . In this regard, disturbances in GFR could be a possible mechanism of diclofenac-induced AKI given that increased plasma urea and creatinine levels, and oxidative stress (observed in this study) correlates to the decline in GFR [51, 52] . Tubular dilatation occurs as a result of increased intracellular osmolality after autolysis shaping as a larger vesicle or even as several smaller vesicles. In accordance with this data, clear vacuoles in renal tubule epithelium are often located in outer cortical tubules and commonly observed in the proximal convoluted tubule epithelium [53, 54] . Despite prostaglandin influence on GFR and NF-B induction of COX-2 expression in most tissues, in this work COX-2 expression was not altered. A possible explanation is that kidney COX-2 expression is regulated by the transcription factor NFAT rather than NF-B [55] . This regulation occurs in a calcineurin-dependent mechanism, given that kidney COX-2 expression was reduced by cyclosporin A (a calcineurin/NFAT signaling inhibitor) treatment [55] . Under stressful conditions, COX-2 expression increases mainly in the macula densa [56] . Given that morphological changes were not observed in the macula densa and that COX-2 expression is dependent on NFAT, but not NF-B in the kidney, the inhibition of COX-2 expression might not be a mechanism of diclofenac intoxication in this experimental conditions. Importantly, vinpocetine reduced histopathological changes compared to the diclofenac-stimulated animals, indicating that vinpocetine confers protection to the renal tissue exposed to diclofenac nephrotoxic doses.
The elevated levels of ROS observed after diclofenac administration indicates that redox signaling also plays a key role in the kidney damage [8] . In fact, in vitro data show that diclofenac induces oxidative stress by affecting kidney mitochondrial complex I, leading to a reduction of ATP formation [12] , and consequently apoptosis [28] and kidney damage. We observed that antioxidant defenses were significantly reduced after diclofenac administration, reflected by lower levels of FRAP and ABTS activity, and GSH levels. Superoxide anion and lipid peroxidation levels were also increased in renal samples. Considering that ROS are linked to the development and progression of AKI [51] , strategies that target oxidative metabolism may represent promising therapeutic approaches. Vinpocetine reduces lipid peroxidation, nitrite production, and restores GSH and total antioxidant defense in different models, such as carrageenan and lipopolysaccharide-induced inflammation [13, 17] , chronic cerebral hypoperfusion-induced vascular dementia [57] , and hepatic ischemia-reperfusion [58] . This mechanism accounts for the scavenging of hydroxyl radicals and other ROS [58, 59] . In fact, vinpocetine presented a similar antioxidant activity to curcumin in a model of ischemia-reperfusion liver injury [58] , a well-known antioxidant molecule [25] . Herein, we observed that treatment with vinpocetine reduced oxidative stress in the kidney corroborating its antioxidant properties. Given the close relationship between ROS and GFR [51, 52] , the antioxidant effect of vinpocetine may explain, at least in part, its renal protective effect. In this work, diclofenac increased the production of the classic proinflammatory cytokines IL-1␤, IL-6, IFN-␥, IL-33, and TNF-␣. Considering that vinpocetine treatment reduced diclofenacinduced cytokine production, and in vitro data demonstrated that diclofenac increases NF-B activation in HCT116 cells [60] , astrocytes [61] , and microglia [62] , the role of NF-B was investigated in diclofenac-induced AKI. To our knowledge, this is the first report demonstrating that diclofenac-induced AKI increases NF-B activation. NF-B modulates cytokine production, and therefore, the increased levels of proinflammatory cytokines might depend on diclofenac-induced kidney NF-B activation. This is consistent with the diclofenac-induced kidney IL-6 mRNA expression [29] and hepatotoxic effects due to increasing IL-1␤, TNFRSF1A expression [63] , and TNF-␣, IFN-␥ production in vitro [64] . Although some reports indicate that diclofenac induces in vivo liver injury [63, 65, 66] , in this experimental conditions, diclofenac did not induce hepatotoxicity. This discrepancy might be attributed to differences in mouse strain or experimental approaches, such as previous LPS priming [65] or chronic treatment [66] . In addition, diclofenac induces in vitro [12] and in vivo [8] kidney nuclear condensation and fragmentation, which can also activate NF-B signaling pathway and apoptosis [67] . Vinpocetine inhibited NF-B expression and activation in renal samples, which lines up with other experimental models, such as in cerebral ischemia-reperfusion injury [18] , TNF-␣- [14] , carrageenan- [17] , and LPS-induced inflammation [13] . Possible mechanisms by which vinpocetine inhibits NF-B signaling pathway include targeting IKK [14] and inhibiting the phosphorylation of the upstream enzyme AKT [19] . Vinpocetine also inhibits PDE-1 [68] and PDE-4 [69] . However, the vinpocetine inhibition of NF-B activation is PDE-independent [14, 19] . This is an important data given that higher levels of plasma proinflammatory cytokines increase the risk of mortality in patients diagnosed with AKI [70] .
We next investigated the expression of the transcription factor c-Myc, which is linked to ROS-, NF-B-, and p53-related apoptotic mechanisms [71] [72] [73] . In fact, mice overexpressing c-Myc develop polycystic kidney disease characterized by intense apoptosis mechanism [74] . Also, under stressful conditions, kidney tubular cells undergo apoptosis in a mechanism dependent on the increases of c-Myc and TNF-␣, and reduction of Bcl-2 [75] . In addition, in vitro evidence demonstrated that the increased expression of c-Myc is associated with the increase of oxidative stress in a model of chemical-induced nephrotoxicity in LLC-PK1 cells (renal tubular cell lineage) [76] . In vitro data using Mantle cell lymphoma (MCL) demonstrated that diclofenac increases p53 and caspase-3 expression, which ultimately lead to apoptosis [77] . Of note, diclofenac as other NSAIDs have been used in cancer models due to their capacity of inducing apoptosis [60, 77] . In this work, diclofenac induced kidney apoptosis, which was reduced by vinpocetine treatment, as observed by c-Myc staining. In fact, vinpocetine reduces the expression of the pro-apoptotic Bax and increases the expression of the anti-apoptotic Blc-2, in addition to its antioxidant capacity [78] . Therefore, these mechanisms may account for the reduced expression of c-Myc in addition to the inhibition of NF-B and ROS.
Despite the two different techniques that were used for the NF-B determination (ELISA and immunohistochemistry), mechanistic studies are necessary to further advance in the investigation on the role of NF-B and its inhibition by vinpocetine in diclofenacinduced AKI. For instance, western blot analysis using kidney cells lineage would allow separating the cytoplasmic and nuclear fractions of NF-B p65 subunit to determine nuclear translocation. The temporal demonstration of NF-B activation would contribute to demonstrate whether this activation depends on the direct effect of diclofenac or it is an event occurring after AKI-triggered ROS production in vivo. Hence, studies using selective NF-B inhibitors would shed light on the role of NF-B in diclofenac-induced AKI. ). The kidney was collected for determination of NF-B activation by measuring the tissue levels of total and phospho-NF-B p65 subunit 24 h after the stimulus. Results are expressed as mean ± SEM, n = 6 mice per group per experiment, two independent experiments ( * p < 0.05 vs. control group; # p < 0.05 vs. 0 mg/kg group, one ANOVA followed by Tukey's post hoc). Results are mean ± SEM, n = 6 mice per group per experiment, two independent experiments ( * p < 0.05 vs. control group; # p < 0.05 vs. 0 mg/kg group, one ANOVA followed by Tukey's post hoc).
Conclusions
We demonstrated that diclofenac induces AKI, which was characterized by increased renal injury biomarkers and oxidative stress plasma levels, in addition to increased tissue oxidative stress, histopathological damages, proinflammatory cytokine production, and apoptosis. Moreover, to the best of our knowledge, this is the first report demonstrating that there is increase of NF-B activation in diclofenac-induced AKI. Also, it is worth to mention that considering immunohistochemistry analysis (NF-B and cMyc proteins expression), diclofenac mainly targets kidney cortical portion. Finally, vinpocetine treatment reduced kidney damage by increasing total antioxidant system defense, and by reducing apoptosis, NF-B activation, and downstream cytokine production. Therefore, this work contributes to the understanding of diclofenac nephrotoxic effects and reveals vinpocetine as a potential approach to treat diclofenac-induced AKI.
